Mediar Therapeutics is pioneering a novel approach to fibrosis treatment by disabling the myofibroblast, the key pathogenic cell in fibrosis that drives scarring, disease progression, and ultimately organ failure
Mediar Therapeutics is pioneering a novel approach to fibrosis treatment by disabling the myofibroblast, the key pathogenic cell in fibrosis that drives scarring, disease progression, and ultimately organ failure. The company is advancing first-in-class antibodies in clinical studies to address fibrosis in several indications including lung (IPF), systemic sclerosis (SSc), and kidney fibrosis.